Oral Cancer Treatment Global Market Report 2024

The oral cancer treatment market size has grown strongly in recent years. It will grow from $1.9 billion in 2023 to $2.04 billion in 2024 at a compound annual growth rate (CAGR) of 7.7%. The growth observed during the historical period can be attributed to interdisciplinary treatment approaches, the implementation of screening programs, advancements in palliative care, innovations in reconstructive surgery, and discoveries in clinical trials.

The oral cancer treatment market size is expected to see strong growth in the next few years. It will grow to $2.66 billion in 2028 at a compound annual growth rate (CAGR) of 6.8%. The anticipated growth in the forecast period can be attributed to regulatory support for innovative therapies, advancements in biomarker research, the expansion of therapeutic options, improvements in screening and early detection, and the increasing adoption of telemedicine and remote monitoring. Major trends expected during the forecast period include global epidemiological changes, regulatory changes and approvals, growing awareness and early detection campaigns, a shift towards patient-centric care, and the utilization of adjuvant therapies.

The anticipated rise in tobacco consumption is set to drive the growth of the oral cancer treatment market. Tobacco, derived from Nicotiana tabacum and other Nicotiana genus plants, contains carcinogens, toxins, and nicotine, contributing to an elevated risk of specific cancers, particularly oral cancer. Notably, The World Health Organization reported that tobacco-related factors lead to over 8 million deaths annually, with 1.3 million non-smokers succumbing to second-hand smoke. Statistics Canada revealed a 5.8% increase in cigarette production compared to June 2021, with a 1.3% rise in total cigarettes sold, reaching 1.4 billion in June 2022. Hence, the escalating tobacco consumption is a significant driver for the oral cancer treatment market.

The growing prevalence of oral cancer is expected to be a key factor propelling the oral cancer treatment market. Oral cancer, characterized by uncontrolled cell growth and invasion affecting oral cavity tissues, is typically treated through surgical resection, radiation therapy, and chemotherapy, depending on the disease's stage. In 2022, the American Cancer Society reported approximately 54,540 new cases of oral cavity or oropharyngeal cancer each year, leading to approximately 11,580 deaths annually. Consequently, the rising incidence of oral cancer stands as a driving force for the growth of the oral cancer treatment market.

The high costs associated with oral cancer treatment are likely to impede market growth. Cancer treatment, known for its high expenses, encompasses various options such as surgery, radiation therapy, and systemic treatments. The escalating costs, extending from diagnosis to ongoing treatment, impose a significant financial burden on patients and their families, contributing to financial distress and compromising their quality of life. According to the National Institutes of Health, the average treatment cost for oral cancer in the UK can range from $3,343 in early stages to $24,890 in advanced stages. Consequently, the substantial costs associated with oral cancer treatment pose a constraint on the oral cancer treatment market's expansion.

Major companies in the oral cancer treatment market are focusing on developing innovative solutions such as CancerDetect to enhance their market profitability. CancerDetect, a screening test for mouth and throat cancer, was launched by Viome Life Sciences Inc. in August 2022. This at-home test aims to detect early-stage oral and throat cancer biomarkers, particularly oral squamous cell carcinoma (OSCC) and oropharyngeal squamous cell carcinoma (OPSCC).

In August 2022, Merck & Co. Inc., a leading pharmaceutical company in oral cancer drug development, collaborated with Orna Therapeutics. This collaboration seeks to accelerate the development of RNA therapies, leveraging the combined expertise of both companies to provide new treatment options for patients. The partnership with Orna Therapeutics aligns with Merck & Co.'s commitment to advancing innovative cancer treatments and improving patient outcomes. Orna Therapeutics, a biotech firm in the United States, specializes in developing treatments for various illnesses, including cancer.

Major companies operating in the oral cancer treatment market report are Pfizer Inc., F. Hoffmann La Roche Ltd., Merck & Co., AbbVie Inc., Novartis AG , Bayer AG, Sanofi-Aventis LLC , Bristol Myers Squibb, AstraZeneca plc, GlaxoSmithKline plc, Eli Lilly and Company, C.H. Boehringer Sohn AG & Co. KG., Viatris Inc., Teva Pharmaceuticals Industries Ltd., MD Anderson Cancer Center, Bausch Health Companies Inc., Memorial Sloan Kettering Cancer Center, Aurobindo Pharma Limited, Cipla Inc., Sun Pharmaceutical Industries Ltd., Lupin Limited, Fred Hutchinson Cancer Research Center, Fresenius Kabi AG, Innovent Biologics Inc., Genentech Inc., Intas Pharmaceuticals Ltd., Ascendis Pharma A/S, Qilu Pharmaceutical Co. Ltd.

North America was the largest region in the oral cancer treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral cancer treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa The countries covered in the oral cancer treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The oral cancer treatment market consists of revenues earned by entities by providing services such as diagnosis and staging, surgical services, radiation therapy, chemotherapy and targeted therapy, immunotherapy, and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The oral cancer treatment market also includes sales of biopsy tools, imaging equipment, endoscopes, surgical instruments, radiation machines, cisplatin, docetaxel, methotrexate, bleomycin sulfate, and pembrolizumab. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The primary types of oral cancer treatment are designed for conditions such as oral squamous cell carcinoma, oral verrucous carcinoma, mucoepidermoid carcinoma, and oral cavity lymphomas. Oral squamous cell carcinoma originates in the squamous cells lining the oral cavity, including the lips, tongue, inner lining of the cheeks, and gums. Various therapeutic modalities include chemotherapy, radiation therapy, and biological therapy, administered through oral, injectable, and other routes. The diverse end users include hospitals, homecare, specialty clinics, and others.

The oral cancer treatment market research report is one of a series of new reports that provides oral cancer treatment market statistics, including oral cancer treatment industry global market size, regional shares, competitors with an oral cancer treatment market share, detailed oral cancer treatment market segments, market trends and opportunities, and any further data you may need to thrive in the oral cancer treatment industry. This oral cancer treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 1-3 business days.